Cytarabine Plus Mitoxantrone Versus Cytarabine Plus Clofarabine As Second-Line Therapy In Aml.

Zartash Gul,Asheesh Jain,Stacey A. Slone,Ali Raufi,Emily Marie Van Meter,Amber Lawson,John W. Hayslip,Gregory Monohan,Dianna S. Howard,Kevin T. McDonagh,Zaid Alkadhimi

JOURNAL OF CLINICAL ONCOLOGY（2013）

引用 0|浏览14

暂无评分

摘要

e18001 Background: There are no comparative studies that can provide guidance about the choice of second line therapy in AML patients (pts). Methods: We retrospectively evaluated 30 consecutive pts...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要